Welcome to our dedicated page for Accolade news (Ticker: ACCD), a resource for investors and traders seeking the latest updates and insights on Accolade stock.
Accolade, Inc. (Nasdaq: ACCD) is a pioneering Personalized Healthcare company devoted to providing exceptional healthcare experiences to millions of people and their families, enabling them to live their healthiest lives. Accolade's range of solutions targets employers, health plans, and consumers by integrating virtual primary care, mental health services, expert medical opinions, and top-tier care navigation. Their innovative platform leverages cloud-based intelligent technology, coupled with expert clinical teams, including registered nurses, physician medical directors, pharmacists, and primary care physicians, to deliver comprehensive advocacy and healthcare services.
The company has been recognized for its significant contributions to the healthcare industry, such as being named one of Forbes' 25 most promising companies and achieving a spot on Inc. 500's list of America's fastest-growing private companies. Accolade's mission is to guide individuals through the complexities of the healthcare system, thereby enhancing outcomes and reducing costs for employers and health plans.
Accolade has recently gained considerable attention for its impressive 227% revenue growth, attributed to a relentless focus on delivering exceptional outcomes. This achievement earned Accolade a place in the Deloitte Technology Fast 500™ list for 2023. CEO Rajeev Singh credits the company's innovative approach and dedicated team for this remarkable performance.
Accolade's Trusted Partner Ecosystem, launched in 2019, exemplifies its commitment to comprehensive healthcare solutions. This ecosystem includes partnerships with leading companies like Kindbody and Noom, expanding access to specialized services such as fertility and metabolic health.
Accolade's financial health remains robust, with recent quarterly results showcasing a significant reduction in net loss and positive adjusted EBITDA, indicating a promising trajectory toward sustainable growth and profitability.
With a consumer satisfaction rating consistently over 90%, Accolade is steadily advancing its vision of transforming healthcare through predictive engagement, proactive care, and by addressing barriers to access and continuity of care. The company's forward-thinking approach ensures it remains at the forefront of healthcare innovation, making a significant impact on the industry and the lives of the people it serves.
For more information, visit accolade.com.
Accolade, Inc. (Nasdaq: ACCD) has partnered with Lyra Health to enhance behavioral health care access for employers. This collaboration, part of Accolade's Trusted Partner Ecosystem, aims to address the barriers faced by U.S. workers in accessing mental health services. A recent Gallup survey revealed over half of workers lack awareness of available resources. Lyra Health provides evidence-based services, aiming for prompt access with an average wait time of only two days for appointments. The partnership promises improved mental health support for joint customers without additional costs.
Accolade, Inc. (NASDAQ: ACCD) announces a significant change in its Board of Directors as Co-founder Michael Hilton transitions from his role as Chief Product Officer to joining the Board, succeeding Tom Neff. Hilton has been pivotal in reshaping Accolade's market strategy since 2015, enhancing its position from a service provider to a product leader. CEO Rajeev Singh commended Hilton's experience, while expressing gratitude for Neff's long-standing contributions. The company's approach combines advanced healthcare services with intelligent technology to improve patient experiences, consistently achieving over 90% consumer satisfaction ratings.
Accolade, Inc. (NASDAQ: ACCD) reported fiscal third quarter 2023 revenue of $90.9 million, a 9% increase from $83.5 million in the same quarter last year. However, the company experienced a significant net loss of $39.9 million, compared to a net income of $22.5 million in fiscal Q3 2022, reflecting a 277% decline. Adjusted EBITDA improved by 14% to $(10.2 million, while adjusted gross profit rose 6% to $41.8 million. The company reaffirmed its 2024 revenue growth and Adjusted EBITDA targets, aiming for positive cash flow by fiscal 2025.
Accolade, Inc. (NASDAQ: ACCD) will engage in the 25th Annual Needham Growth Conference on January 11, 2023, hosting a fireside chat at 1:30 pm ET. The event will be accessible via a webcast and replay on their investor relations website. Accolade offers healthcare solutions that enhance the patient experience through personalized, data-driven services. The company boasts a consumer satisfaction rating exceeding 90%, reflecting its commitment to improving healthcare outcomes and lowering costs.
Accolade, Inc. (NASDAQ: ACCD) announced it will release its fiscal third quarter 2023 financial results on January 9, 2023, after market close. The company will host a conference call at 4:30 p.m. E.T. to review the results. Accolade provides healthcare solutions to millions, emphasizing a personalized and value-based approach that includes virtual primary care and expert medical opinions. The company consistently achieves consumer satisfaction ratings above 90%. For more details, visit their website.
Accolade, Inc. (Nasdaq: ACCD) is advocating for equitable healthcare as a Health Equity Impact Champion sponsor at HLTH 2022. The company has welcomed FOLX Health, an LGBTQIA+ affirming care provider, into its Trusted Partner Ecosystem, enhancing its offerings to over 11 million members. Accolade's Chief Medical Officer and Deloitte Managing Director discussed employers' roles in improving healthcare access. The Trusted Partner Ecosystem, now celebrating three years, integrates various health solutions, providing significant value to employers and improving healthcare experiences for marginalized communities.
Accolade, Inc. (NASDAQ: ACCD) reported fiscal Q2 2023 revenue of $87.6 million, marking a 20% increase from $73.3 million in Q2 2022.
The company achieved a net loss of $46.5 million, improved by 25% year-over-year.
Adjusted gross profit grew by 31% to $39.2 million with a margin of 44.7%.
Accolade raised its revenue guidance for fiscal 2023 and anticipates positive cash flow and Adjusted EBITDA in fiscal year 2025.
Accolade, Inc. (NASDAQ: ACCD) will release its fiscal Q2 2023 financial results on October 6, 2022, after market close. A conference call to discuss the results will occur at 4:30 p.m. E.T. on the same day. Accolade provides personalized healthcare solutions, serving over 600 employers and millions of members, combining virtual care, mental health support, and care navigation. The company boasts a consumer satisfaction rating exceeding 90%. For more details, visit accolade.com.
Accolade, Inc. (NASDAQ: ACCD) announced participation in two investor conferences on September 13, 2022. The Morgan Stanley 20th Annual Global Healthcare Conference will occur at 10:35am ET, followed by the Baird’s 2022 Global Healthcare Conference at 10:50am ET. The company focuses on enhancing healthcare experiences through virtual primary care, mental health support, and intelligent care navigation, boasting over 90% consumer satisfaction ratings. Webcasts and replays will be available on their investor relations site.
FAQ
What is the current stock price of Accolade (ACCD)?
What is the market cap of Accolade (ACCD)?
What does Accolade, Inc. do?
How has Accolade performed financially recently?
What is the Trusted Partner Ecosystem?
Who are Accolade's key partners?
What recognition has Accolade received?
What is Accolade's mission?
How does Accolade contribute to healthcare cost reduction?
How does Accolade engage with its members?
What is Accolade's customer satisfaction rating?
Where can I find more information about Accolade?
